364 related articles for article (PubMed ID: 37480814)
1. Unlocking the potential of PROTACs: A comprehensive review of protein degradation strategies in disease therapy.
Bhole RP; Kute PR; Chikhale RV; Bonde CG; Pant A; Gurav SS
Bioorg Chem; 2023 Oct; 139():106720. PubMed ID: 37480814
[TBL] [Abstract][Full Text] [Related]
2. PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).
He M; Cao C; Ni Z; Liu Y; Song P; Hao S; He Y; Sun X; Rao Y
Signal Transduct Target Ther; 2022 Jun; 7(1):181. PubMed ID: 35680848
[TBL] [Abstract][Full Text] [Related]
3. Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance.
Zhu H; Wang J; Zhang Q; Pan X; Zhang J
Pharmacol Ther; 2023 Apr; 244():108371. PubMed ID: 36871783
[TBL] [Abstract][Full Text] [Related]
4. PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs.
Maneiro M; De Vita E; Conole D; Kounde CS; Zhang Q; Tate EW
Prog Med Chem; 2021; 60():67-190. PubMed ID: 34147206
[TBL] [Abstract][Full Text] [Related]
5. PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras.
Madan J; Ahuja VK; Dua K; Samajdar S; Ramchandra M; Giri S
BioDrugs; 2022 Sep; 36(5):609-623. PubMed ID: 36098871
[TBL] [Abstract][Full Text] [Related]
6. Effective degradation of EGFR
Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
[TBL] [Abstract][Full Text] [Related]
7. PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies.
Sincere NI; Anand K; Ashique S; Yang J; You C
Molecules; 2023 May; 28(10):. PubMed ID: 37241755
[TBL] [Abstract][Full Text] [Related]
8. Delivering on Cell-Selective Protein Degradation Using Chemically Tailored PROTACs.
Yao R; Luo T; Wang M
Chembiochem; 2023 Oct; 24(19):e202300413. PubMed ID: 37496112
[TBL] [Abstract][Full Text] [Related]
9. Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future.
Li R; Liu M; Yang Z; Li J; Gao Y; Tan R
Molecules; 2022 Dec; 27(24):. PubMed ID: 36557960
[TBL] [Abstract][Full Text] [Related]
10. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
[TBL] [Abstract][Full Text] [Related]
11. New-generation advanced PROTACs as potential therapeutic agents in cancer therapy.
Wang C; Zhang Y; Chen W; Wu Y; Xing D
Mol Cancer; 2024 May; 23(1):110. PubMed ID: 38773495
[TBL] [Abstract][Full Text] [Related]
12. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
Reboud-Ravaux M
Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
[TBL] [Abstract][Full Text] [Related]
13. PROTAC-DB 2.0: an updated database of PROTACs.
Weng G; Cai X; Cao D; Du H; Shen C; Deng Y; He Q; Yang B; Li D; Hou T
Nucleic Acids Res; 2023 Jan; 51(D1):D1367-D1372. PubMed ID: 36300631
[TBL] [Abstract][Full Text] [Related]
14. PROTACS: A technology with a gold rush-like atmosphere.
Wang YW; Lan L; Wang M; Zhang JY; Gao YH; Shi L; Sun LP
Eur J Med Chem; 2023 Feb; 247():115037. PubMed ID: 36566716
[TBL] [Abstract][Full Text] [Related]
15. PROTAC-DB: an online database of PROTACs.
Weng G; Shen C; Cao D; Gao J; Dong X; He Q; Yang B; Li D; Wu J; Hou T
Nucleic Acids Res; 2021 Jan; 49(D1):D1381-D1387. PubMed ID: 33010159
[TBL] [Abstract][Full Text] [Related]
16. Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniques.
Chen S; Cui J; Chen H; Yu B; Long S
Eur J Med Chem; 2023 Dec; 262():115911. PubMed ID: 37924709
[TBL] [Abstract][Full Text] [Related]
17. Recent Developments in Medicinal Chemistry and Therapeutic Potential of Anti-Cancer PROTACs-Based Molecules.
Irshad Khan MZ; Nazli A; Pan YL; Chen JZ
Curr Med Chem; 2023; 30(14):1576-1622. PubMed ID: 35927805
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in targeted protein degraders as potential therapeutic agents.
Yang N; Kong B; Zhu Z; Huang F; Zhang L; Lu T; Chen Y; Zhang Y; Jiang Y
Mol Divers; 2024 Feb; 28(1):309-333. PubMed ID: 36790583
[TBL] [Abstract][Full Text] [Related]
19. Potential of the nanoplatform and PROTAC interface to achieve targeted protein degradation through the Ubiquitin-Proteasome system.
Xie H; Zhang C
Eur J Med Chem; 2024 Mar; 267():116168. PubMed ID: 38310686
[TBL] [Abstract][Full Text] [Related]
20. Breaking Bad Proteins-Discovery Approaches and the Road to Clinic for Degraders.
Bouvier C; Lawrence R; Cavallo F; Xolalpa W; Jordan A; Hjerpe R; Rodriguez MS
Cells; 2024 Mar; 13(7):. PubMed ID: 38607017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]